Clarity Pharmaceuticals Hits Fifth Undetectable Prostate Cancer Case in SECuRE Trial

• Fifth patient with undetectable PSA and negative PSMA PET after Cu-SAR-bisPSMA treatment
• Participant achieved undetectable PSA after first cycle and negative PET after second cycle
• Treatment well tolerated with only mild, mostly resolved adverse events
• Ongoing recruitment in Phase II with Phase III registrational trial planning underway